Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Pliant Therapeutics (PLRX) Net Margin (2020 - 2023)

Pliant Therapeutics has reported Net Margin over the past 4 years, most recently at 16609.68% for Q2 2023.

  • Quarterly Net Margin fell 1601745.0% to 16609.68% in Q2 2023 from the year-ago period, while the trailing twelve-month figure was 68847.98% through Mar 2024, down 6748876.0% year-over-year, with the annual reading at 10211.14% for FY2023, 893782.0% down from the prior year.
  • Net Margin was 16609.68% for Q2 2023 at Pliant Therapeutics, down from 2818.92% in the prior quarter.
  • Over five years, Net Margin peaked at 343.46% in Q3 2020 and troughed at 16609.68% in Q2 2023.
  • The 4-year median for Net Margin is 1276.19% (2021), against an average of 2507.46%.
  • Year-over-year, Net Margin soared 68396bps in 2022 and then crashed -1601745bps in 2023.
  • A 4-year view of Net Margin shows it stood at 426.14% in 2020, then tumbled by -188bps to 1227.16% in 2021, then crashed by -45bps to 1784.22% in 2022, then tumbled by -831bps to 16609.68% in 2023.
  • Per Business Quant, the three most recent readings for PLRX's Net Margin are 16609.68% (Q2 2023), 2818.92% (Q1 2023), and 1784.22% (Q4 2022).